Results 31 to 40 of about 773,646 (162)

Early detection of ovarian cancer [PDF]

open access: yesEuropean Radiology, 2020
Abstract Early detection is the only way to achieve a high cure rate in women with ovarian cancer. Unfortunately, to date, there is no effective strategy for early detection, despite rapidly emerging biomarkers. The low prevalence of ovarian cancer, low specificity and high rates of false positives have been limitations of screening programs.
openaire   +2 more sources

Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy

open access: yesJournal of Experimental & Clinical Cancer Research, 2022
Background Therapeutic strategies engaging the immune system against malignant cells have revolutionized the field of oncology. Proficiency of dendritic cells (DCs) for antigen presentation and immune response has spurred interest on DC-based vaccines ...
Natacha Jugniot   +2 more
doaj   +1 more source

Early Detection of Ovarian Cancer [PDF]

open access: yesDisease Markers, 2007
Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Less than 30% of women with advanced stage disease survive long‐term. When diagnosed in stage I, up to 90% of patients can be cured with conventional surgery and chemotherapy. At present, only 25% of ovarian cancers are detected in stage I due, in part, to
Badgwell, Donna, Bast Jr., Robert C.
openaire   +2 more sources

Early detection of pancreatic cancer

open access: yesCurrent Opinion in Gastroenterology, 2020
Purpose of review Pancreatic cancer is the third leading cause of cancer death and with a dismal 5-year survival of 10%. Poor survival of pancreatic cancer is mostly due to its presentation and diagnosis at a late stage. The present article aims to update clinicians with recent progress in the field of early detection of ...
Sushil Kumar, Garg, Suresh T, Chari
openaire   +6 more sources

Interpretable and integrative analysis of single-cell multiomics with scMKL

open access: yesCommunications Biology
The rapid advancement of single-cell technologies has led to the development of various analysis methods, each with trade-offs between predictive power and interpretability particularly for multimodal data integration.
Samuel D. Kupp   +5 more
doaj   +1 more source

Can computed tomography predict nodal metastasis in breast cancer patients?

open access: yesThe Egyptian Journal of Radiology and Nuclear Medicine, 2022
Background Axillary lymph node metastasis is considered one of the main prognostic factors clinically used for the evaluation of breast cancer patient.
Sherihan Fakhry   +3 more
doaj   +1 more source

Early Detection of Pancreatic Cancer

open access: yesJOP : Journal of the pancreas, 2012
Despite treatment advances pancreatic cancer remains one of the most lethal malignancies. It is expected that early detection and screening of high risk patient population may have the most significant impact on altering overall survival in this disease. Serologic biomarkers may be the most useful in early detection and histology-based markers may have
Vasco, Eguia   +2 more
openaire   +2 more sources

Early Detection of Cancer: An Overview [PDF]

open access: yesAnnual Review of Public Health, 1988
There are two types of preventive services: primary prevention acts to reduce the probability of disease before its onset by decreasing exposure to risk factors; secondary prevention (early detection) identifies the disease at an early stage so that effective treatment can be administered sooner than would have otherwise been possible.
R N, Battista, S A, Grover
openaire   +2 more sources

Early detection of lung cancer [PDF]

open access: yesF1000Research, 2016
Most patients with lung cancer are diagnosed when they present with symptoms, they have advanced stage disease, and curative treatment is no longer an option. An effective screening test has long been desired for early detection with the goal of reducing mortality from lung cancer.
openaire   +2 more sources

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

open access: yesNature Communications
Daratumumab is approved for patients with multiple myeloma (MM) and high-risk smoldering MM (HR-SMM). However, HR-SMM is often as genomically complex as MM, suggesting it may be too advanced for single-agent intervention. We report on a Phase II trial of
Omar Nadeem   +32 more
doaj   +1 more source

Home - About - Disclaimer - Privacy